Tarsus Pharmaceuticals, Inc. (TARS) key performance indicators and operating metrics (8 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Gross Margin | 94.00 percent | FY2026-Q1 |
| High-Value Website Actions Increase | 40.00 percent | FY2026-Q1 |
| XDEMVY Peak Sales Potential | 2B | FY2026-Q1 |
| Gross-To-Net Discount | 44.00 percent | FY2025-Q4 |
| Coverage Across Commercial, Medicare, and Medicaid | 90.00 percent | FY2025-Q4 |
| Year-Over-Year Net Sales Growth | 128.00 percent | FY2025-Q4 |
| XDEMVY Bottles Delivered to Patients | 130K | FY2025-Q4 |
| XDEMVY Reimbursement Coverage (Covered Lives) | 90.00 percent | FY2025-Q1 |
Back to TARS overview · TARS earnings · TARS holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.